PCSK9, the short track road from discovery as drug target towards the clinic.

27 August 2016 (15:35 - 15:50)

Organised by:

About the speaker

Professor Gilles Lambert

INSERM, SAINT DENIS (Réunion)

4 More presentations in this session

Presentation thumbnail

Introduction - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.

Professor W. Koenig (Munich, DE) Professor K. Ray (London, GB)

Presentation thumbnail

A clinical perspective on PCSK9 inhibition: what do we know and what can we expect?

Doctor P. Ridker (Boston, US)

Presentation thumbnail

Preparing for a novel era in CV prevention: where do PCSK9 inhibitors fit in lipid management?

Professor J. Kastelein (Amsterdam, NL)

Presentation thumbnail

Discussion & summary - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.

Professor W. Koenig (Munich, DE) Professor K. Ray (London, GB)

Access the full session

Session thumbnail

PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities

The Event

ESC Congress 2016

27 August 2016 15:35 CET

You may be interested in

Congress Presentation

Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study

1 September 2025

Congress Presentation

RNA-based therapy in dyslipidaemia

27 August 2023

Congress Presentation

GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences

20 June 2025

Congress Presentation

Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia

2 September 2019

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources